Yazhou Li

机构：National Institutes of Health, National Institute on Aging · ORCID：0000-0002-6048-3660

发表论文 95 篇 · 总被引 7142 次 · h-index 40

代表论文

• Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment (2022 · Pharmacological Research · 被引 281)
• The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial (2023 · Brain · 被引 155)
• Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial (2025 · The Lancet · 被引 149)
• The RhoA-ROCK1/ROCK2 Pathway Exacerbates Inflammatory Signaling in Immortalized and Primary Microglia (2023 · Cells · 被引 55)
• DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease (2024 · GeroScience · 被引 26)
• Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration (2024 · Biomolecules · 被引 23)